ReviewJournal of Crohn's & colitis2026
Evaluating sonographic response and remission in inflammatory bowel disease: aligning intestinal ultrasound assessment with STRIDE-II timelines.
Review in Journal of Crohn's & colitis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsThe diagnostic accuracy of intestinal ultrasound (IUS) is established; however, guidance on the timing and interpretation of sonographic response and remission in inflammatory bowel disease (IBD) remains limited. This review synthesizes current evidence to define expected response and remission kinetics in Crohn's disease (CD) and ulcerative colitis (UC) across STRIDE-II aligned reassessment timepoints.
methodsA structured narrative review was undertaken of studies published up to August 31, 2025 evaluating longitudinal IUS changes following initiation of medical therapy in patients with CD and UC. Outcomes were synthesized across early (<3 months), intermediate (3-6 months), and longer-term (6-12 months) reassessment intervals aligned with STRIDE-II timelines.
resultsIn CD, sonographic response was reported in approximately 51%-66% of patients by 12 weeks, while remission was reported in 14%-37%. At 3-6 months, response was reported in approximately 36%-38%, while remission was reported in 12%-38%. Longer-term response and remission were reported in approximately 36%-57% and 24%-42%, respectively, at 48-56 weeks. In UC, response was reported in 57%-77% and remission in 45%-64% by weeks 8-12 in selected cohorts. However, traditional IUS response and remission estimates beyond this early treatment phase remain limited in UC. Direct comparisons between studies was limited by heterogeneity in outcome definitions, reassessment timepoints, therapy class, and disease characteristics.
conclusionIUS is a practical, non-invasive tool for monitoring therapeutic response in IBD. The optimal timing of reassessment is likely to vary according to therapy-specific time to response, IBD subtype, disease phenotype, and bowel segment. Standardization of definitions and reassessment timelines remain central to integrating IUS into treat-to-target models of IBD care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.